← Back to Search

Cannabinoid

CBD for Glucose Tolerance in Diabetes

N/A

Waitlist Available

Research Sponsored by Christopher Bell

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Free of gastrointestinal or metabolic diseases

18 years of age and older

Timeline

Screening 3 weeks

Treatment Varies

Follow Up compared to baseline after 4 weeks of the intervention

Awards & highlights

Study Summary

This trial will study if CBD can help prevent diabetes by improving glucose tolerance and the gut microbiota.

Who is the study for?

This trial is for adults over 18 who weigh more than 110 pounds, are relatively inactive, and have a BMI of at least 25. They should not have gastrointestinal or metabolic diseases but may be at risk for diabetes. Those pregnant, breastfeeding, with certain diseases (like inflammatory bowel disease), on specific medications, or with known allergies to CBD cannot participate.Check my eligibility

What is being tested?

The study tests if Cannabidiol (CBD) powder can improve glucose tolerance and positively alter the gut microbiota in people at risk for diabetes. Participants will either receive the CBD powder or a placebo without active ingredients to compare effects.See study design

What are the potential side effects?

While not explicitly listed in the provided information, common side effects of CBD may include tiredness, diarrhea, changes in appetite/weight. However, participants with adverse reactions to CBD products are excluded from this trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I do not have any stomach or metabolic diseases.

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ compared to baseline after 4 weeks of the intervention

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~compared to baseline after 4 weeks of the intervention

This trial's timeline: 3 weeks for screening, Varies for treatment, and compared to baseline after 4 weeks of the intervention for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Abundant microbiota to markers in feces

B-diversity scores for all fecal samples to assess clustering

Circulating blood glucose

+20 more

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: Dietary Supplement: Cannabidiol (CBD) powder formulationActive Control1 Intervention

T-P-S-10 Caliper powder - 30 mg CBD in the form of 300 mg of 10% CBD isolate

Group II: Dietary Supplement: CBD matching PlaceboPlacebo Group1 Intervention

Matching Placebo

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Christopher BellLead Sponsor

7 Previous Clinical Trials

168 Total Patients Enrolled

Caliper FoodsUNKNOWN

Media Library

Cannabidiol (CBD) powder formulation (Cannabinoid) Clinical Trial Eligibility Overview. Trial Name: NCT05285449 — N/A

Diabetes Research Study Groups: Dietary Supplement: Cannabidiol (CBD) powder formulation, Dietary Supplement: CBD matching Placebo

Diabetes Clinical Trial 2023: Cannabidiol (CBD) powder formulation Highlights & Side Effects. Trial Name: NCT05285449 — N/A

Cannabidiol (CBD) powder formulation (Cannabinoid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05285449 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this study open to recruitment at the moment?

"Clinicaltrials.gov has indicated that the trial is still available to potential patients, as it was initially posted on February 9th 2022 and edited just recently on March 9th."

Answered by AI

How many participants are engaged with this research endeavor?

"Affirmative. Clinicaltrials.gov lists this clinical trial as actively enrolling members, with the first post dating back to February 9th 2022 and the latest update on March 9th of that same year. This experiment requires 30 participants across a single medical centre."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Influence of Cannabidiol on Glucose Tolerance and The Gut Microbiota

Christopher Bell 2022. "Influence of Cannabidiol on Glucose Tolerance and The Gut Microbiota". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05285449.

All > Cbd > Epidiolex